HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Previous close
$2.46
Day range
$2.53 - $2.96
Year range
$0.97 - $9.79
Market cap
13.39M USD
Avg Volume
895.12K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.87M | 76.44% |
Net income | -1.77M | 17.87% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.87M | 15.24% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 13.28M | 105.07% |
Total assets | 13.44M | 96.12% |
Total liabilities | 1.27M | 1.68% |
Total equity | 12.17M | — |
Shares outstanding | 4.80M | — |
Price to book | 0.96 | — |
Return on assets | -48.81% | — |
Return on capital | -55.41% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -1.77M | 17.87% |
Cash from operations | -1.28M | 36.60% |
Cash from investing | -2.00K | — |
Cash from financing | 9.17M | 229,425.00% |
Net change in cash | 7.90M | 491.86% |
Free cash flow | -721.00K | 40.20% |
About
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Founded
2011
Headquarters
Website
Employees
5
